OM-85 BV, an immunostimulant in pediatric recurrent respiratory tract infections: a systematic review by Schaad, Urs
World J Pediatr, Vol 6 No 1 . February 15, 2010 .  www.wjpch.com
5
OM-85 BV in pediatric respiratory infections
System
atic review
Author Affi liations: Division of Pediatric Infectious Diseases, University 
Children's Hospital, Basel, Switzerland (Schaad UB) 
Corresponding Author: Urs B Schaad, MD, Division of Pediatric 
Infectious Diseases, University Children's Hospital Basel (UKBB), 
Römergasse 8, CH-4005 Basel, Switzerland (Tel: +41 61 685 62 56; Fax: 
+41 61 685 60 01; Email: urs-b.schaad@unibas.ch)
doi:10.1007/s12519-010-0001-x
©2010, World J Pediatr. All rights reserved.
Background: This study was conducted to assess the 
effi cacy of OM-85 BV (Broncho-Vaxom) in the prevention 
of pediatric recurrent respiratory tract infections (RTIs). 
Available evidence suggests that defi ning recurrent RTIs 
as ≥3 infections per fall-winter semester is both medically 
and epidemiologically justifi ed. Therefore, this criterion 
was chosen as a primary endpoint. 
Methods: Trials were identifi ed through consultation 
of bibliographic databases and other channels. Eleven 
non-blinded studies plus one dealing with primary 
prevention were excluded and eight randomized 
controlled trials were included in the meta-analysis. The 
data were compared at 6 months, which represented the 
end of most studies. The complete database was examined 
according to the guidelines of the Cochrane collaboration.
Results: The mean age of children and the number 
of RTIs in the preceding year were comparable at 
admission. Of the patients in the OM-85 BV treated 
population (n=435), 32% had recurrent RTIs (that is, 
≥3 RTIs/6 months) vs. 58.2% in the placebo treated 
population (n=416; P<0.001). Sensitivity analysis showed 
that this was not driven by any particular trial. The 
results of this review were also positive for the active 
treatment regarding the secondary variables, which were 
represented by the number of patients with at least one 
RTI and the mean number of RTIs. 
Conclusions: This meta-analysis shows, as observed 
in several individual trials, that the population treated with 
OM-85 BV had signifi cantly and consistently fewer cases of 
recurrent RTIs. The data suggest that the effect is greater in 
patients at increased risk of recurrent RTIs.
World J Pediatr 2010;6(1):5-12
Key words: children; 
                   immunostimulant; 
                   OM-85 Broncho-Vaxom; 
                   recurrent respiratory tract infections 
Introduction
OM-85 BV (Broncho-Vaxom) is an immunostim-ulant medication used to prevent recurrent respiratory tract infections (RTIs). The 
mechanism of its action has recently been reviewed 
by Rozy et al.[1] OM-85 BV has been shown to induce 
the terminal maturation of human dendritic cells, with 
an enhanced T cell-stimulatory capacity in vitro.[2] The 
broncho-alveolar lavage of adults treated with OM-85 
BV[3,4] showed an increase in the helper/suppressor T 
lymphocyte ratio, a stimulation of the impaired alveolar 
macrophage activity, and increased concentrations of 
interferon-γ.
The clinical aspects of recurrent pediatric RTIs have 
been dealt with in detail in a recent systematic review,[5] 
including pathogenesis, prevention and "key" trials with 
OM-85 BV. Therefore, the paper presented herein shall 
concentrate on a meta-analytic approach, attempting to 
quantify the effectiveness of OM-85 in the secondary 
prevention of recurrent RTIs in children. 
It is widely accepted that recurrent RTIs in 
childhood represent a problem per se in addition 
to increasing predisposition to future respiratory 
problems. Repeated lower RTIs in the fi rst 3 years 
of life show a positive association with wheezing 
up to the age of 7 years.[6] However, the concept 
of recurrence in relation with RTIs presents some 
problems since there is no generally agreed defi nition. 
Preschool children may contract between four and six 
RTIs over the course of a year without this representing 
a true deviation from "normality".[7] In a German study 
it was shown[8] that the number of febrile episodes 
in the fi rst year of life was superior to three in about 
28% of the infants and that about 9% had two or 
more courses of antibiotics. Several episodes seem 
"normal" since several peaks of exposure to different 
agents occur during each season.[9] Some authors[10] 
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have attempted to defi ne recurrence of infection by 
clinical presentation, e.g., three episodes of otitis over 
6 months or two episodes of sinusitis and/or recurrent 
bronchopneumonia in 6 months or four episodes of 
rhinopharyngitis in 6 months. Such a classifi cation, 
particularly in younger children, however seems 
somewhat artifi cial. Therefore, epidemiological and 
clinical observations favor the concept that the term 
"recurrent" should be reserved for cases of several 
RTIs per fall-winter season, e.g., three or more.[5,11]
Several factors such as day care in local nursery and 
short duration of breastfeeding predispose to recurrent 
RTIs, particularly otitis media, as well as to wheezy 
bronchitis,[12] and should therefore be considered as co-
variates in clinical studies.
In addition to being the most frequent causative 
agents of respiratory disease, viral infections can 
predispose to bacterial superinfection. The proportion 
of children with mixed viral and bacterial RTIs found in 
studies using serology or antigen detection in serum or 
urine has been reported to be as high as 40%. However, 
these methods may be inadequate for assessing the 
clinical importance of bacterial infection or the need for 
antimicrobial treatment.[13]
In order to provide a more accurate quantitative 
estimate of the overall treatment effects of a frequently 
employed immunostimulant, we performed a meta-
analysis of studies in children with a history of recurrent 
RTIs. As in adults,[14] limiting the assessment to the 
proportion of children without any RTI after treatment 
with an immunostimulant may provide a biased picture, 
so the cut-off was therefore set at 3 or more RTIs over 6 
months.
Methods
Objective
The primary objective of this meta-analysis was to 
provide a more accurate estimate of the overall treatment 
effects of OM-85 BV from a clinical point of view, 
choosing clinically relevant end points as described in 
the study by Schaad et al.[11] The cut-off for the outcomes 
was set at 6 months; the following criteria were defi ned a 
priori (RTI as defi ned in each study protocol):
1) Primary endpoint: proportion of patients with 
recurrent RTIs (that is ≥3 RTIs per 6 months);
2) Secondary endpoints: proportion of patients with at 
least one RTI and mean number of RTIs during 6 months.
No distinction was made between the different 
clinical diagnoses of RTIs. Since the frequency of RTIs 
decreases with the age of children and since the number 
of RTIs in the current season correlates with the number 
of events in the preceding year,[11,15] examination of 
these two variables as a control of comparability of 
the patient populations at admission to the trial was 
decided upon. The guidelines provided by the Cochrane 
Collaboration Handbook for Reviews[16] have been 
applied in the analysis of the clinical data.
Search strategy
The data sources for the identifi cation of trials included 
bibliographic databases (TOXLINE, MEDLINE, 
HealthSTAR, AIDSLINE and CANCERLIT, Embase, 
AMED, Cochrane Library, PudMed (/www.ncbi.nlm.
nih.gov), TOXMAP, TOXLINE Special, DART Special, 
HSDB, IRIS, ITER, GENETOX, CHEMIDplus, Haz-
Map), hand-searching reference lists from pertinent 
review articles and books, and personal contacts with 
experts active in the area and manufacturers up to April 
2009. Full disclosure of the product documentation 
including requested statistical and offi cial reports by 
the manufacturer in Switzerland warranted a minimal 
publication bias. All papers were screened, and any 
dealing with prospective clinical trials were retained 
for classifi cation according to the selection criteria 
described below. In case of double publications, the 
authors retained those which were most recent and/or 
had been published in a peer-reviewed journal.
All trials eligible were summarized in a tabulated 
format. The standard table included a full reference, a 
quality rating, the type of pathology, demographic data 
and treatments, end-points and adverse events. The 
trials dealing with pediatric respiratory tract infections 
were retained.
Material scrutinized
The electronic databases identifi ed recurrent infections, 
OM-85, Broncho-Vaxom, Imocur, placebo, double-
blind and infants (age, 1-23 months) / children (age, 2-12 
years) in 22 publications. Two additional publications of 
clinical studies were identifi ed through other channels 
as mentioned above, and duly scrutinized.
Five studies were descriptive, open-labelled 
pediatric studies and one was a cost-effectiveness model 
analysis; these had to be discarded. Ten comparative 
studies were excluded as they did not comply with 
one or more criteria (Table 1).[17-26] Eight studies were 
retained as relevant trials dealing with secondary 
prevention, and were retained for closer examination 
(Table 2).[11,27-33] Four of these trials were conducted 
in Western Europe and the remaining four in Mexico: 
they were all totally or partially industry-sponsored.
Selection criteria
Initially, all articles, published and unpublished trials, 
were considered for review. They were subsequently 
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classifi ed by study design, screened and weighted, 
based on their methodological quality (methods, 
participants, interventions, outcome measures and 
results). Quality assessment was based on a rating of 
the trials by the criteria published by Jadad et al.[34]
Eleven studies were excluded as they were non-
blinded or incomplete. Nine studies were retained as 
relevant trials and, fi nally, eight dealing with secondary 
prevention were included in the meta-analysis (Table 
2).[11,27-33] All trials only admitted children with a 
documented history of recurrent RTIs.
Regarding similarities and differences in the 
trials selected, the study of Schaad et al[11] required 
the patients to actually have an episode of RTI at 
admission, while all the other studies only admitted 
children with a documented history of recurrent RTIs. 
The patients studied by Gomez-Barreto et al[28] had 
sinusitis, and those reported by Zagar and Löfl er-
Badzek[33] had chronic rhinosinusitis. The trial of Jara-
Perez and Berber[30] included only girls living in an 
orphanage, and the trial of Del-Rio-Navarro et al[27] 
included children with subnormal serum IgG. Jara-
Perez and Berber[30] and Schaad et al[32] provided clinical 
descriptions of the RTIs which are not discussed herein.
The dosing schedules used in the trials included in 
this meta-analysis are shown in Table 3.
Statistical analysis
Data were extracted from the pertinent publications 
and/or study reports in order to obtain for each of 
the selected trials the key variables defi ned as end-
points and the demographic data deemed of interest 
as set forth in the trial by Schaad et al[11] (age of the 
patient and number of RTIs over the preceding 12 
months, number of patients completing trial). These 
data were checked for consistency and adequacy of 
tests employed. Missing data were reconstructed 
through iterative procedures. The completed database 
was entered in Review Manager 2.4.7 software of the 
Cochrane collaboration; binary data were examined by 
the Peto-Mantel-Haenszel test.[35] Whenever the authors 
specifi ed two sets of data, the intent to treat analysis 
was chosen. The denominator 'N' indicated the number 
of patients reported by the authors; if not specifi ed, 
'N' was the number of patients who were admitted to 
the trial. Sensitivity analysis was made by sequential 
elimination of trials and by elimination of outlier trials, 
with an outlier being defi ned as "an extreme value that 
Table 2. Summary of trials screened and selected rating by Jadad criteria
Table 1. Summary of comparative trials screened and excluded (alphabetically)
Author (year) Recurrent RTIs? Double blind? Placebo? Age 1-12 y? Reasons for exclusion
Ahrens (1984) Yes Yes? Yes No Not adequate blinding, age not as
  defi ned
Chen (2007) Wheezing No budesonide Yes Indication, not adequate blinding,
  no placebo 
Collet (1993) Primary prevention Yes Yes Yes Indication 
Field (1998) Primary prevention No vs. previous year Yes Indication, no blinding, no placebo 
Gutiérrez-Tarango (1997) Yes No Conventional treatment Yes No blinding, no placebo 
Kapellerova (1989) Yes No "Bacterial vaccine" Yes No blinding, no placebo 
Maestroni (1984) Predisposition Yes? Yes No Indication, not adequate blinding,
  age not as defi ned
Martin du Pan (1982) No No Yes Yes Indication, not adequate blinding 
Quezada (1999) Yes + hypogammaglobulinemia No Yes Yes Indication, not adequate blinding 
Ziuzio (1994) Allergy No Polyvaccium; IRS-19 Yes Indication, no blinding, no placebo 
Jadad criteria Prevention
Secondary Primary
Del-Rio
  (2003)
Schaad
  (2002) 
Gutierrez-T.
  (2001)*
Jara-Perez
  (2000)
G.-Barreto
  (1998)†
Paupe
  (1990)
Zagar
  (1988)
Schaad
  (1986)
Collet
  (1993)
Is the study randomized? Y Y Y Y Y Y Y Y Y
Is the study double-blinded? Y Y Y Y Y Y Y Y Y
Is there a description of withdrawals? Y Y Y Y Y Y Y Y Y
Is the randomization adequately described? P Y P P P P No P Y
Is the blindness adequately described? P Y P P P Y No P Y
Score 4 5 4 4 4 4.5 3 4 5
Y (yes): 1 point; P (partial): 0.5 points; No: 0 point. *: 12 months trial; the values at 6 months were considered for the current analysis. †: after 
sinusitis.
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might have a low probability of occurrence but cannot 
be statistically shown to originate from a different 
distribution than the rest of the data".[36] Additional 
and exploratory analyses were made employing the 
WinSTATTM for Excel Version 2001.1. 
Results
Key demographic data, comparability at baseline
As described in the Methods section, since the age of 
the children and the number of RTIs in the preceding 
year are correlated with the number of RTIs to be 
expected during the trial, these two variables were 
regarded as a control of comparability of the patient 
populations at admission to the trial.
The mean number of RTIs in the previous year 
was similar in the two populations (mean of studies 
with the information: 6.12±3.74 RTIs in the OM-85 
BV populations vs. 6.23±3.52 RTIs in the placebo), 
but no such information was available in the study by 
Gomez-Barreto[28] while the study by Paupe[31] provided 
some other relevant information about the similarity 
between therapeutic groups. With these caveats, the 
patient population can be accepted as homogeneous. 
The number of drop-outs is comparatively small in both 
therapeutic groups; in the majority of the cases, patients 
dropped out because of administrative reasons.
In Table 4 the mean ages at admission (pooled mean & 
SD) and the number of patients are depicted, whereas Table 
5 shows the mean number of RTIs in the previous year.
Proportion of patients with RTIs
Although the data were heterogeneous, 32% of the 
patients within the OM-85 BV treated population had 
recurrent RTIs (≥3 RTIs per 6 months), vs. 58.2% of 
the placebo treated population, indicating that the active 
treatment led to 26.2% fewer patients with recurrent 
RTIs (Fig. 1). The large proportion of placebo patients 
without recurrent RTIs is probably best explained by 
the natural trend of children to suffer from fewer RTIs 
as they grow older.
Sensitivity analysis by sequential elimination 
of trials yielded odds ratios between 0.42 and 0.6, 
and signifi cance level unchanged at P<0.001. After 
elimination of the outlier trials by Jara-Perez,[30] which 
showed the largest difference between treatments, 
and by Schaad,[32] which tilted towards placebo, the 
database became homogeneous, showing that there 
Table 3. Dosing schedules employed in examined trials
Author (year) mon 1 mon 2 mon 3 mon 4 mon 5 mon 6 mon 7 mon 8 mon 9 mon 10 mon 11 mon 12
Del-Rio (2003)
Schaad (2002)
Gutierrez-Tarango (2001)
Jara-Perez (2000)
Gomez-Barreto (1998)
Paupe (1990)
Zagar (1988)
Schaad (1986)
Cut-off
Collet (1993) Primary prevention; Excluded
Gray areas: one capsule OM-85 BV in the morning. One capsule OM-85 BV for children contains 3.5 mg of lyophilized bacterial lysates of 
Haemophilus infl uenzae, Diplococcus pneumoniae, Klebsiella pneumoniae and ozaenae, Staphylococcus aureus, Streptococcus pyogenes and 
viridans, Neisseria catarrhalis.
Table 4. Mean ages at admission (pooled mean & SD) and number of patients
Author (year) Age (y) OM-85-BV Age (y) placebo N patients OM-85-BV N patients placebo
Mean SD Mean SD Intent to treat Completed Intent to treat Completed
Schaad (2002) 5.19 1.42 5.27 1.37 120   98 100   85
Gutierrez-Tarango (2001) 3.86 2.44 4.52 2.70   26   26   28   27
Del Rio (2003) 4.00 0.90 4.10 0.90   25   22   24   21
Jara-Perez (2000) 9.76 1.89 9.62 1.88 100   99 100 100
Gomez-Barreto (1998) 4.69 1.72 4.06 1.81   26   26   30   30
Paupe (1991) 6.60 5.30 7.60 5.30   64   61   63   55
Zagar (1988) 6.53 5.08 6.81 4.50   29   29   22   22
Schaad (1986) 4.33 2.79 4.09 2.49   45   45   49   49
Pooled mean & SD 6.27 3.60 6.41 3.57 435 406 416 389
Completed (%) 93.3% 93.5%
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were 20.2% fewer patients with recurrent RTIs within 
the remaining OM-85 BV treated population than in the 
placebo treated population. 
By the observations of individual trials, one may 
conclude that the population treated with OM-85 BV 
had signifi cantly and consistently fewer patients with 
recurrent RTIs (≥3 RTIs per 6 months) by between 
26.2% and 20.2% (the latter as a conservative estimate 
after obtaining a homogeneous database by eliminating 
the outlying trials). Likewise and as expected, there 
is also a signifi cant reduction in the relative risk (RR 
(fi xed) & 95% CI: 0.56 [0.48, 0.66]) and in the odds 
ratio (OR (fi xed) & 95% CI: 0.33 [0.25, 0.45]). 
In both treatment groups, the majority of children 
had at least one RTI during the study period (Table 
6). Although the data were somewhat heterogeneous, 
over 16.2% of patients had no RTI in the period under 
consideration within the OM-85 BV treated population 
(27.3% with OM-85 BV vs. 11.1% with placebo). 
Likewise, there was also a signifi cant reduction in the 
odds ratio (OR OM-85 BV: placebo was 0.33 [95% 
CI: 0.23, 0.49]). Sensitivity analysis by sequential 
elimination of trials yielded odds ratios between 0.38 
and 0.52, signifi cance level unchanged at P<0.001. 
The trials therefore indicated that the population 
treated with OM-85 BV had signifi cantly and 
consistently fewer patients with one or more RTIs in a 
6-month period (Table 6). Moreover, after elimination 
of the largest favorable "outlier", i.e., the trial of Del-
Rio-Navarro[27] in children with IgG defi ciencies, and 
the worst trial outcome for this variable,[11] this fi gure 
was 17.0%, which was even more signifi cant.
Mean number of RTIs in 6 months
The analysis of the mean number of RTIs over 6 months 
had to be regarded with some caution since the data 
were actually ordinal (that is, natural whole numbers) 
and not all trials were suitable for such an analysis 
because of differences in variances. Nevertheless, the 
mean number of RTIs was signifi cantly lower in the 
OM-85 BV treated population, by an average of -1.15 
(95% CI: -1.55, -0.75) RTIs/6 months (Table 7). After 
eliminating the outlier studies for this variable (i.e., 
Schaad et al (2002) 
Del Rio (2003) 
Jara-Perez (2000) 
Gutierrez-T. (2001) 
G.-Barreto (1998) 
Paupe (1990) 
Zagar (1988) 
Schaad (1986) 
POOLED DATA 
-40.0%    -20.0%       0.0%        20.0%       40.0%      60.0%     80.0% 
Favors OM-85Favors placebo
Fig. 1. Percent difference (and 95% confidence interval) between 
treatments for patients with recurrent RTIs (≥3 RTIs/6 months).
Table 5. Mean N RTIs in the previous year
N RTIs previous year OM-85 BV Placebo 
Mean SD Mean SD
Schaad et al (2002)   5.76 2.38   6.06 2.13
Gutierrez-Tarango (2001) 12.62 4.82 12.32 3.85
Del Rio (2003)   9.40 3.70 10.10 2.80
Jara-Perez (2000)   4.94 0.76   5.09 0.70
Gomez-Barreto (1998) No data No data
Paupe (1991) N RTIs >4: 54% N RTIs >4: 58%
Zagar (1988)   6.72 6.40   5.59 6.46
Schaad (1986)   3.76 1.86   3.82 1.82
Table 6. Number of patients with RTIs (≥1 or ≥3 RTIs/6 months), per trial & treatment
 Author (year) 1 or more RTIs 3 or more RTIs
OM-85-BV Placebo OM-85-BV Placebo
Schaad et al (2002) 103 (85.8%)   87 (87%)   39 (32.5%)   44 (44%)
Gutierrez-Tarango (2001)   23 (85.2%)   28 (100%)   14 (51.9%)   23 (82.1%)
Jara-Perez (2000)   86 (86%) 100 (100%)   14 (14%)   70 (70%)
Del Rio (2003)     2 (10%)   20 (100%)   14 (70%)   19 (95%)
Paupe (1990)   37 (60.7%)   46 (83.6%)   19 (31.1%)   34 (61.8%)
Zagar (1988)     8 (27.6%)     9 (40.9%)     1 (3.4%)     5 (22.7%)
Schaad (1986)   39 (86.7%)   48 (98%)   28 (62.2%)   28 (57.1%)
Gomez-Barreto (1998)   13 (50%)   21 (70%)     8 (30.8%)   12 (40%)
Pooled (signifi cance: P<0.001)* 311 (72.7%) 359 (88.9%) 137 (32%) 235 (58.2%)
Number needed to treat 6.2 3.8
Odds ratios OM-85-BV: placebo 0.33 (95% CI 0.23, 0.49) 0.33 (95% CI 0.25, 0.45)
"Robust analysis" after deleting Jara-Perez (2000) as positive 'outlier' & Schaad (1986) as negative 'outlier': 
Pooled (signifi cance: P<0.001) 186 (65.7%)* 211 (82.7%)   95 (33.6%)† 137 (53.7%)
*: Test for heterogeneity: P=0.001 for 1 or more RTIs, P<0.00001 for 3 or more RTIs; †: Test for heterogeneity: P>0.1.
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Gutierrez-Tarango[29] & Schaad[32]) the mean number of 
RTIs continued to be signifi cantly lower in the OM-85 
BV treated population, by an average of -1.10 (95% CI: 
-1.64, -0.56) RTIs/6 months.
The weighted mean difference (WMD; also defi ned 
as "effect size") between mean numbers of RTIs over 
6 months was -1.21 [95% CI: -1.39, -1.03] in favor 
of the active treatment (P<0.00001), although the test 
for heterogeneity was also highly signifi cant. This 
heterogeneity was probably due to the differences in age of 
patients and in the number of RTIs in the preceding year. 
Several co-variates were likely to infl uence the 
outcomes and might explain the heterogeneity found in 
some variables. They were briefl y illustrated, although 
they had not been submitted to a formal analysis. The 
mean number of RTIs was consistent with the number 
of RTIs in the preceding year and with the age of the 
patients (Fig. 2). Namely, the number of RTIs in the 
preceding year appeared to have a major bearing on 
the results, the benefi t of OM-85 BV was markedly 
greater in children with a history of very frequent RTIs 
(confi rmed by multiple stepwise regression analysis in a 
subset of trials with raw data available, data not shown). 
Table 7. Mean number of RTIs in 6 months (pooled mean & SD) by treatment 
N RTIs/6 months OM-85 BV Placebo Comments
Mean SD Mean SD
Schaad et al (2002) 2.12 1.44 2.48 1.63
Gutierrez-Tarango (2001) 5.04 1.95 8.00 2.51 Variances,* P=0.06
Del Rio (2003) 2.80 1.40 5.20 1.50
Jara-Perez (2000) 1.43 0.94 2.99 0.81
G.-Barreto (1998) 1.56 1.53 2.22 2.43
Paupe (1991) 2.07 2.09 3.51 2.97 SD estimated†
Zagar (1988) 0.38 0.71 1.09 1.50 Variances,* P=0.003
Schaad (1986) 2.89 1.77 2.98 1.56
Pooled mean & SD 2.09 1.79 3.24 2.40 P<0.001
Pooled mean & SD after eliminating 'outlier' trials of Gutierrez-Tarango (2001) & Schaad (1986)
Pooled mean & SD 1.78 2.51 2.88 4.21 P<0.001
*: Bartlett-Test for homogeneity of variances; †: SD estimated to be equal to average ratio SD/mean of the other trials.
The quality assessment of the studies, i.e., the 
Jadad rating system, had no evident infl uence on the 
outcomes. The funnel plots, which should be regarded 
as a generic instrument for examining small study 
effects rather than a tool to diagnose specifi c types of 
bias, did not suggest the existence of publication or any 
other major bias in this meta-analysis.
Safety
The incidence of minor adverse events in the clinical 
trials was 17.7% for the OM-85 BV treated and 
18.2% for the placebo treated patients; the majority 
of adverse events were gastrointestinal or cutaneous 
fi ndings. Serious adverse events were reported in 1% 
vs. 0.5%, withdrawals due to adverse event in 1.3% 
vs. 0.7%, respectively. No causal relationship has 
been established for any of these adverse events. No 
laboratory abnormalities in relation with OM-85 BV 
have been reported in the literature. There were neither 
deaths nor serious adverse events attributed or possibly 
attributable to the study medication.
Discussion
Steurer-Stey et al[37] used a partially meta-analytical 
approach of published data with OM-85 BV; their 
fi ndings, however, remained fragmentary due to failure 
to request additional information from the manufacturer 
or other sources. Moreover, their report also analyzed 
other bacterial immunostimulants. They concluded that 
their "systematic review provides weak evidence that oral 
immunostimulation with bacterial extracts prevents acute 
RTIs in children." There was a trend for fewer infections 
over 6 months of follow-up in children not in day care as 
well as a small reduction in number of antibiotic courses.
Our study showed that with the active treatment 
there were 26.2% fewer patients with recurrent RTIs Fig. 2. Differences (and 95% confi dence interval) between treatments, mean number of RTIs by N RTIs in the year before admission.
2        4               6           8          10         12
N RTIs previous 12 mon
Differences between means & 2 SEM
Favors placebo
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s &
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EM
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
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Favors OM-85
Gutierrez-T, 2001
Del Rio, 2003
Jara-P., 2000
Zagar, 1988
Schaad, 2002
Schaad, 1986
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(i.e., ≥3 RTI/6 months). The fact that the population 
of the different trials included in the meta-analysis 
is homogeneous (after excluding the two 'outliers') 
in terms of this variable lends strength to the highly 
signifi cant results in favor of OM-85 BV. 
The proportion of patients with any RTI (i.e., ≥1 
RTI/6 months) was reduced by 16.2% in our study, but 
this variable is of lesser clinical relevance in view of the 
multiple agents which can cause acute symptoms of an 
RTI during one single season, probably involving different 
defence mechanisms. Sensitivity analysis was made for 
all variables and no particular trial driving the effi cacy 
outcomes was identifi ed, thus corroborating the results. 
In line with similar analyses,[38,39] the mean number of 
RTIs was reduced by 35.5% but the data, although a 
highly signifi cant difference was found in favor of OM-85 
BV, are very heterogeneous. The heterogeneity in the 
secondary outcomes is probably explained by clinical and 
methodological diversity, dependent on the age, the risk of 
RTIs (as N RTIs in the preceding year) and other variables. 
For example, the 'outlier' study of Jara-Perez[30] had several 
particular characteristics as it was conducted under the 
very controlled conditions of an orphanage for girls. 
Exploratory analysis indicates that effi cacy is more 
pronounced in patients at high risk of recurrent RTIs; 
the benefi t of OM-85 BV as compared to placebo was 
notoriously greater in children with a history of very 
frequent RTIs.
The infl uence of industry-sponsoring on the outcomes 
of trials has been discussed controversially; that is, no 
infl uence was found in some cases[40] while in others the 
results tipped in favor of the sponsored drug.[41] Meta-
analysis sponsored by industry came to more "drug-
friendly" conclusions than independent studies, even if 
the estimated treatment effect was similar.[42]
The positive and negative predictive value of meta-
analysis should be taken into consideration. Agreement 
between meta-analyses and large clinical trials of 
therapeutic interventions can be expected in 68% of the 
cases, while a statistically signifi cant difference was 
found in only 12% of the cases; in no case, however, 
there was a divergence in which the randomized 
clinical trial and the meta-analysis yielded statistically 
signifi cant and opposite results.[43] It is important to note 
that the outcomes concerning the primary variable were 
homogeneous in robust analysis since heterogeneity 
in the outcomes of individual trials appears to be an 
important predictor of discrepancy between meta-
analyses and large clinical trials.[44]
We believe that this analysis may help both the 
practitioner in identifying the best candidates for this 
immunostimulant therapy and the investigators in 
setting up new randomized controlled trials in this 
complex fi eld. Future studies should provide details 
of the RTIs occurring during the observation period 
employing a standardized clinical classifi cation.
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